Medicaid programs decide state by state whether to pay for GLP-1 drugs such as Wegovy and Zepbound when they are prescribed for weight loss. The drugs generally stay covered for type 2 diabetes, but obesity coverage has been shrinking as costs rise.
California, New Hampshire, Pennsylvania, and South Carolina ended weight-loss coverage on January 1, 2026, and Rhode Island followed on October 1, estimating $20.3 million in combined state and federal savings. In Ohio, an administrative rule bars coverage for adult obesity, and the Obesity Action Coalition is pressing the state to change it.
A University of Pittsburgh study in JAMA, published November 16, 2026, measured the effect of the January cuts. Prescriptions in the four states fell from 2,914 to 421 per 100,000 beneficiaries in one quarter, about 84% relative to states that kept coverage, and prescriptions for diabetes-approved versions did not rise significantly.
See #wegovy, #glp-1, and #discontinuation.
University of Pittsburgh researchers found that in California, New Hampshire, Pennsylvania, and South Carolina, Medicaid prescriptions for GLP-1s approved for weight loss fell from 2,914 to 421 per 100,000 beneficiaries between late 2025 and early 2026, versus 3,006 to 2,758 in 10 states that kept coverage. Pennsylvania's drop was 95.5%. The authors estimate 175,500 to 526,600 fewer beneficiaries may have filled prescriptions, and they saw no significant shift to diabetes-approved GLP-1s.
Ohio Medicaid covers GLP-1 drugs for type 2 diabetes, heart risk reduction, sleep apnea, MASH, and obesity in patients under 18, but an exclusion in the state's administrative code blocks coverage for adult obesity, and the agency said it "cannot simply start covering these drugs under current policy," the Journal-News reported. Sarah Bramblette of the Obesity Action Coalition is pushing for a change, which would require formal rulemaking reviewed by the Joint Committee on Agency Rule Review or new legislation. KFF counts 13 state Medicaid programs that covered the drugs for weight management as of early 2026.
As of Thursday, October 1, 2026, Rhode Island Medicaid no longer covers GLP-1 drugs such as Wegovy, Zepbound, and Saxenda when they are prescribed for weight loss, Rhode Island Current reported; the drugs remain covered for other conditions such as type 2 diabetes. The program paid for 24,971 GLP-1 prescriptions for obesity in fiscal year 2025, and state officials estimated the change would save $6.3 million in state general revenue and $20.3 million in combined state and federal funds. California, New Hampshire, Pennsylvania, South Carolina, Utah, and Massachusetts also ended or did not renew Medicaid obesity coverage this year.